The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MNMD | +39.13% | -6.98% | -1.44% | +35% |
| S&P | +13.96% | +91.24% | +13.85% | +118% |
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $890.77M | 0.0% |
| Market Cap / Employee | $12.04M | 0.0% |
| Employees | 74 | 29.8% |
| Net Income | -$67.27M | -391.6% |
| EBITDA | -$45.67M | -84.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $19.96M | -93.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $40.39M | 66.1% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -60.39% | -18.0% |
| Return On Invested Capital | -57.75% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.84M | -73.1% |
| Operating Free Cash Flow | -$29.84M | -73.1% |
| Metric | Q2 2024 | Q2 2024 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.81 | 2.81 | 2.20 | 4.82 | 71.58% |
| Price to Tangible Book Value | 3.13 | 3.13 | 2.42 | 5.40 | 72.71% |
| Enterprise Value to EBITDA | -10.24 | -9.55 | -10.08 | -18.48 | 146.85% |
| Return on Equity | -68.0% | -37.1% | -59.1% | -85.6% | 56.73% |
| Total Debt | $21.85M | $22.04M | $41.19M | $40.39M | 66.12% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
